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Objectives: Due to its dramatically increasing prevalence, type 2 diabetes mel-
litus (T2DM) is a serious public health concern in Saudi Arabia. Few data have been 
published that describe how persons with T2DM are managed in clinical practice; 
we aimed to characterize recent treatment patterns among individuals treated 
for T2DM in Riyadh, Saudi Arabia. MethOds: Charts from 455 adults with T2DM 
who visited the King Fahad National Guard Hospital from October 2009 to March 
2010 (enrolment period) were systematically sampled until the target (n= 250) 
was reached. Treatment data from enrolment to September 2011 were abstracted 
from subject charts. Treatment regimens, their frequency of use, and the num-
ber of switches (drug replacement/removal/addition) over the study period were 
calculated. Analyses were stratified by T2DM duration; data for those recently-
diagnosed (< 5 years; n= 29) and with longstanding disease (≥ 20 years; n= 67) are 
presented. Results: Forty-four percent of subjects were male; at enrolment, mean 
(SD) age was 61 (13) years, and mean T2DM duration was 11 (8) years. At enrolment, 
42% of subjects had received prior insulin treatment (recently-diagnosed: 23%; long-
standing disease: 52%). During the study period, the most common regimens were 
oral combination therapy (41%) and insulin+oral combination therapy (32%). Overall, 
44% received any insulin therapy during the study period (recently-diagnosed: 25%; 
longstanding disease: 54%). By study end, 49% had received any prior insulin therapy 
(recently-diagnosed: 29%; longstanding disease: 58%). On average, T2DM subjects 
had 1.3 treatment switches over the period; little variation was seen by T2DM dura-
tion. cOnclusiOns: Although the frequency of insulin treatment was lower than 
reported in other studies from the region, treatment switches are indicative of 
attempts to improve T2DM control. Novel therapies may improve clinical outcomes 
among T2DM patients and this study provides valuable baseline data with which to 
compare the effectiveness of new T2DM treatments in Saudi Arabia.
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usage of self-moniToring of BlooD glucose (smBg) By DiaBeTes 
TheraPy TyPe in inDia
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Objectives: SMBG is a core component of diabetes therapy, supporting a safe and 
effective drug therapy and providing feedback on the impact of diet and lifestyle. In 
2014 an Indian guideline on glycemic monitoring was published. This study aims 
to assess the level of SMBG usage in patients by diabetes therapies. MethOds: 
Source data for this explorative analysis is the CSD-PDS Diabetes survey covering 
drug treated patients with diabetes. All 2,250 cases were documented in the 2nd 
half of 2013. PDS Diabetes is a syndicated research with a fixed representative 
panel of doctors from larger Indian cities using a standardized documentation of 
cases. SMBG usage is analyzed by therapeutic subgroups: oral diabetes therapy 
(OAD 75%), basal supported oral therapy (BOT 9%), conventional insulin therapy 
(CT 8%), intensive insulin therapy (IIT 5%) and others (3%, excluded). Results: 
Diabetes type 2: 93%. 1,180 patients (52.4%) have a meter for home-testing. 
Shares of testers by therapies (OAD/ BOT/CT/IIT) are 50.7%, 63.4%, 53.1% and 
67.3%. An HbA1c-goal of 8% is achieved by 62/49/45/37%, an HbA1c-goal of 7% by 
29/20/19/18%. Average weekly test frequencies are 2.4, 2.8, 2.9 and 2.2 respectively. 
In the OAD/BOT/CT groups 13/14/16% test at least once daily (recommended), less 
than 2% in IIT test 3 times daily (recommended). HbA1c levels are by 0.3%, 0.2%, 
1.1% and 0.0% lower in SMBG users. cOnclusiOns: Many patients in this sample 
do not achieve HbA1c targets and many do not test their blood glucose. Below 1 
in 5 patients follows the recommended test frequency. In IIT SMBG is needed to 
support insulin dose adjustments: below 1 in 50 test enough. In CT patients the 
differences in HbA1c between testers and non-testers are largest. Lacking benefit 
in IIT treated patients might indicate the insufficiency of current testing. The new 
guideline might help to close these gaps.
gasTroinTesTinal DisorDers – clinical outcomes studies
Pgi1
The comParison of clinical imPacT BeTween enTecavir anD 
Tenofovir in chronic hBv infecTion
Shen W.C., Tsai P.Y., Kuo L.N.
Taipei Medical University and Wan Fang Hospital, Taipei, Taiwan
Objectives: To compare the efficacy and safety of Entecavir and Tenofovir in 
nucleos(t) ide-naïve CHB patients with HBV DNA in a medical center. MethOds: We 
included patients in WFH had used Entecavir or Tenofovir from 2011/07 to 2012/12, 
and excluded patients who had (1) co-infection with the HCV, HIV, TB, (2) the his-
tory of malignancy within 3 years before the first time use of ETV or TDF, (3) the 
history of alcohol abuse, and (4) used other anti-HBV drugs. In Statistics, we used 
Kaplan–Meier survival analysis to present the HBV DNA suppression and the nor-
malization of ALT. Results: We identified 124 consencutive patients treated with 
ETV and 24 patients treated with TDF. After 18 months, the probability of complete 
viral suppression was 67.7% in the ETV group and 45.8% in the TDF group (P= 0.49). 
The probability of complete ALT normalization was 87.1% in the ETV group and 
83.3% in the TDF group (P= 0.159). In the adverse side effects of neurologic, malaise 
was observed in the patients treated with ETV more than TDF (11.3% vs. 0%), but in 
gastrointestinal disorders, diarrhea was observed in the patients treated with TDF 
more than ETV (25.0% vs. 3.2%). cOnclusiOns: Entecavir and Tenofovir have no 
rithms compared to the conventinal glucose control using paper-based proto-
cols. MethOds: A systematic literature review and meta-analysis was used to 
evaluate the safety and effectiveness for the automated target glucose control. 
The 14 randomized control trials of 2537 articles were selected and two reviewers 
evaluated independently the quality of this selected articles using the Scottish 
Intercollegiate Guidelines Network (SIGN) tool. Results: The computer-based 
insulin protocols resulted in a shorter time to reach within target range (MD -1.03, 
95%CI -1.70~-0.35, p= .003, I2= 77%) and a higher percentage of glucose readings 
within target range (MD 11.98, 95%CI 8.83~15.14, p< .001, I2= 89%) than the paper-
based protocols. The incidence rates of above or below target range in computer-
based insulin protocols were acceptable levels and the incidence rates of severe 
hypoglycemia below 40mg/dL in computer-based insulin protocol was significantly 
lower than the paper-based insulin protocols (MD -23.41, 95%CI -32.35~-14.46, p< . 
001, I2= 0%). cOnclusiOns: The automated target glucose control using com-
puter-based algorithms resulted in tighter glycemic control without an increased 
risk of hypoglycemic events compared to the paper-based protocols. But taking 
into account the high heterogeneity between studies, these results must be inter-
preted with caution.
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Objectives: A comparisons of economic methods across all NICE submissions 
for SGLT-2is (dapagliflozin, canagliflozin and empagliflozin) and exploring poten-
tial opportunities for optimising the appraisals of treatment classes. MethOds: 
The NICE website was searched for: manufacturer submissions, clarification 
letters, evidence review group (ERG) reports and NICE guidance relating to the 
SGLT-2is. Data extracted included the sources of inputs and key assumptions to 
the economic analysis in particular the evidence synthesis, modelling approach 
and key cost-effectiveness results. Comparisons were then made across apprais-
als in reference to the ERG and NICE comments to identify any areas of uncer-
tainty. Results: The results of the review indicated the following similarities 
between submissions: The lines of therapies explored; the use of United Kingdom 
Prospective Diabetes Study equations to link surrogate to clinically relevant out-
comes; use of Bayesian network meta-analyses to derive clinical inputs which 
were all based on the same studies, outcomes and time period; the sources of 
cost and utility inputs were mainly derived from UKPDS studies; and the relative 
differences in costs and QALYS. The main differences identified included: the eco-
nomic models used (pre-existing versus de Novo); treatments included in decision 
space; the modelling of weight gain; definitions of adverse effects included; and 
the total costs and QALYs between appraisals. cOnclusiOns: The NICE apprais-
als for SGLT-2is were broadly similar in their overall design. This is apparent from 
the similar results of the appraisals in terms of relative outcomes. Given this, it is 
arguable whether the resources required to develop these separate submissions 
was essential. It would be of value for HTA organisations to develop reference 
cases including standard inputs for the modelling of significant conditions such 
as diabetes especially where there is such consistency. This would improve the 
comparability of analyses and reduce the costs to manufacturers and ERGs in 
developing and reviewing submissions respectively.
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aDherence To nice guiDance for iniTiaTing glP-1 mimeTics among 
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Objectives: To assess adherence to UK NICE guidance/guidelines for initiating 
therapy with Glucagon-Like Peptide-1 [GLP-1] mimetics - exenatide, prolonged-
release exenatide [Exen-PR] and liraglutide – in patients with Type 2 diabetes 
(T2D). MethOds: A retrospective cohort study of T2D patients in primary care 
identified in the CPRD. Patients were ≥ 40 years at GLP-1 initiation, had ≥ 12 months 
of CPRD history, with first GLP-1 prescription recorded on/after publication of the 
respective NICE guidance/guideline. The primary outcome was the proportion of 
patients initiating/not initiating GLP-1 as part of a NICE-recommended regimen (rec-
ommended dual therapy: liraglutide or Exen-PR added to metformin or sulphonylu-
reas; recommended triple therapy: any GLP-1 added to metformin+sulphonylureas 
or metformin+thiazolidinedione). For patients initiating GLP-1 as triple therapy, 
the proportion meeting NICE initiation criteria (HbA1c ≥ 7.5% and body mass 
index [BMI] ≥ 35kg/m2) was assessed. Results: Mean age of the study cohort ini-
tiating GLP-1 (7,133 patients) was 58.2 years (SD 9.4), BMI 38.4 kg/m2 (SD 6.8) and 
HbA1c 9.2% (SD 3.2%). Overall, only 25% (1,772/7,133) of patients were initiated on 
GLP-1 as part of a NICE-recommended regimen. Approximately 13% of patients 
initiated liraglutide (443/3,438) and 13% initiated Exen-PR (45/346) as part of NICE-
recommended dual therapy regimen, with a higher proportion initiating a GLP-1 as 
part of NICE-recommended triple therapy (exenatide: 19% [637/3,349], liraglutide: 
17% [588/3,438], Exen-PR: 17% [59/346]). Of those patients initiated on a recom-
mended triple therapy regimen, 50% fulfilled both NICE HbA1c and BMI initiation 
criteria. The majority of the study cohort (75%) initiated GLP-1 in combination regi-
mens not recommended by NICE: 12% non-recommended dual therapy; 21% non-
recommended triple therapy; 16% monotherapy, and 25% quadruple therapy/add-on 
to insulin. cOnclusiOns: Many patients are initiated on GLP-1 in combination 
regimens which are not recommended by NICE. The rationale for these decisions 
may warrant further research to better understand the observed low adherence to 
NICE-recommended regimens.
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Objectives: To study possible associations and assess the impact of socio-demo-
graphic, quality-of-life and coping factors on the severity of Crohn’s disease patients 
in Israel. MethOds: Consecutive Crohn’s disease patients undergoing clinical follow-
up at the Inflammatory Bowel Diseases Clinic completed the following question-
naires: SF-36 quality-of-life, Ways of Coping, and socio-demographic details. Crohn’s 
disease severity was measured by Harvey-Bradshaw Index (HBI) expanded to include 
pharmaceutical and surgical therapies as well as medical and surgical hospitalization 
information. Based on these data, a multifactorial model was built using multivariate 
linear regression. Results: There were altogether 192 patients: 81 (42.2%) men (age 
36.8 ± 14.5 years, disease duration 11.4 ± 8.6 years, education 13.7 ± 2.7 years, HBI 7.6 
± 4.9) and 111 (57.8%) women (age 41.4 ± 15.6*, duration 14.0 ± 9.3*, education 14.2 ± 
2.8, HBI 8.4 ± 4.8; *p < 0.05 vs. men). The multifactorial model showed the following 
significant predictors of disease severity: age (beta = −0.250, p = 0.006), number of 
children (beta = 0.245, p = 0.008), SF-36 General Health score (beta = −0.378, p < 0.01), 
coping/sense of humor (beta = 0.209, p = 0.011), and coping/acceptance (beta = −0.183, 
p = 0.024). The model accounted for 29% of explained variance, with Adjusted R2 = 
0.26. Gender, education and socio-economic status were not predictors of disease 
severity. cOnclusiOns: All of the indicated factors (age, family size, coping skills) 
had a significant effect on the severity of Crohn’s disease. In addition to prescribing 
medications, physicians should pay special attention to these factors as part of an 
overall management plan for their Crohn’s disease patients.
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DeveloPmenT anD exTernal valiDaTion of a risk calculaTor for 
PreDicTing anemia in PaTienTs TreaTeD wiTh TriPle TheraPy (TT) 
conTaining BocePrevir (Boc), PegylaTeD inTerferon anD riBavirin (Pr)
Nwankwo C.1, Kattan M.2, Luan A.3, Wahl J.1
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Objectives: To develop and validate a risk calculator for the prediction of anemia 
occurring after 8 weeks of TT using BOC+PR among Hepatitis C Virus (HCV) genotype 
1 patients based on risk factors. MethOds: Data for all randomized HCV genotype 
1 patients starting therapy with BOC+PR and who received at least one dose of BOC 
in three phase 3 clinical trials (PN05101, PN5216 and PN5514) were included. The 
outcome of interest was the prediction of anemia, defined as hemoglobin < 10 g/L 
after 12 weeks of TT with BOC+PR (this included 4 weeks of lead-in treatment using 
PR). Logistic regression was used to develop the risk calculator model by analyzing 
the association of each variable with the likelihood of developing anemia while on 
treatment. Baseline variables were included as covariates in the model. Linearity 
assumptions were relaxed with the use of restricted cubic splines. Bootstrapping, 
with 1000 resamples, were used in conjunction with estimation of discrimination 
and calibration. Results: Following a stepdown procedure that eliminated predic-
tors that did not contribute to the overall model concordance index, nine variables 
remained in the final model: age, hemoglobin, gender, cirrhosis, hematologic counts, 
Alkaline phosphatases levels, and creatinine. This model had a boostrap corrected 
concordance index of 0.775. The model was cross-validated by sequentially omit-
ting each of the three randomized trials from the model development and using the 
omitted trial as a test set; the concordance indices following this procedure ranged 
from 0.75 to 0.85. Calibration of the model, assessed graphically, indicated reason-
ably close agreement between predicted and observed proportions. Calibration held 
following trial cross validation as well. cOnclusiOns: The model calibrated well 
and demonstrated good predictive ability. This tool may be useful for identifying 
and subsequently managing HCV patients at relatively high risk for developing 
anemia if treated with BOC+PR.
gasTroinTesTinal DisorDers – cost studies
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Objectives: Hepatitis C virus (HCV) infection is one of the main causes of chronic 
liver disease worldwide. Sofosbuvir, a nucleotide analogue inhibitor of HCV RNA-
dependent RNA polymerase, has been approved in Europe for the treatment of 
chronic hepatitis C genotypes 1-6. This study aims to estimate the budget impact 
of sofosbuvir in patients who live in the Veneto Region. MethOds: Population data 
were obtained from a regional survey. The survey was conducted by the Department 
of Molecular Medicine of Padua University in order to identify the number of 
patients with advanced stage disease or more rapid disease progression. At the 
time of this study, the Italian price of sofosbuvir has not been defined so it was esti-
mated that a full 12 week course of sofosbuvir would cost as Swedish price: 42.653 
€ (85.306€ for a 24 week treatment). Total costs include costs for other drugs which 
might be used in combination. Results: In Veneto Region, there are 835 patients 
with severe Hepatitis C genotype 1 (n= 493); genotype 2 (n= 94), genotype 3 (n= 178), 
genotype 4 (n= 70) and about 40% of them need a 24 week treatment. Moreover, 
there are 100 patients awaiting liver transplantation and 70 patients with post-
transplant recurrence of HCV infection. Therefore, the total estimated expenditure 
would be about € 66.000.000 for all the 1005 patients and about € 34.000.000 for the 
455 patients (45%) with very high priority to treatment. cOnclusiOns: High prices 
for new drugs are a growing concern to payers, given the large number of innova-
tive drugs in development and the limited health care resources. Due to high costs, 
economic analyses are needed to estimate the budgetary impact for the Regional 
Health System (RHS) with sofosbuvir.
significance difference in the efficacy and safety in nucleos(t) ide-naïve CHB patients 
with HBV DNA greater than 6 log10 in the medical center.
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effecTiveness of ProBioTics in irriTaBle Bowel synDrome:  
a sysTemaTic review wiTh meTa-analysis
Nikfar S, Mozafari S, Didari T, Abdollahi M
Tehran University of Medical Sciences, Tehran, Iran
Objectives: To investigate the efficacy of probiotics in irritable bowel syndrome 
(IBS) patients, this meta-analysis was performed. MethOds: The collected data 
contained twenty-four clinical trials which fifteen were eligible for meta-analysis 
and nine were reviewed systematically. All studies were randomized placebo-con-
trolled trials in patients with IBS that investigated the efficacy of probiotics in IBS 
improvement. Trials were evaluated with Relative Risk (RR) with 95% confidence 
interval (95% CI). Cochran Q test was used to test heterogeneity with P value 0.05 
(P< 0.05). Egger and Begg-Mazumdar tests in funnel plot were calculated as publica-
tion bias indicators. Results: Probiotics reduced pain severity, symptom severity 
score and induced adequate general symptom improvement. Distension, bloating, 
and flatulence were not improved after probiotics treatment when compared to 
placebo. cOnclusiOns: Collectively, the results demonstrated the beneficial effi-
cacy of probiotics compared with placebo in IBS patients.
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Objectives: Hepatitis C virus (HCV) affects an estimated 130 million people world-
wide and is a major cause of chronic liver disease. Real-world data is needed to bet-
ter understand the epidemiology of HCV and its complications, as well as treatment 
patterns and outcomes. The objectve of this study is to establish a cohort of HCV 
carriers in a large health maintenance organization, with comprehensive data on 
treatment and disease outcomes. MethOds: The HCV cohort will use data available 
since 1998 from the computerized databases of Maccabi Healthcare Services, the 
second largest HMO in Israel, with approximately 2 million members. HCV cases are 
included based on diagnostic codes (ICD9-CM), laboratory data (e. g. detection of HCV 
antibodies and RNA) and dispensed prescriptions for HCV treatment. The cohort 
includes demographic data (age, sex, immigration and socioeconomic status), clini-
cal data (e. g. BMI; comorbidities), treatment patterns, virological outcomes, and HCV 
complications – including cirrhosis, hepatocellular carcinoma, liver transplants, and 
mortality. Results: At the end of 2012, HCV infection was identified among 10,648 
patients, corresponding to an age-adjusted prevalence rate of 5 per thousand. The 
highest prevalence was found among males and in the age group 35-55 yrs. Two 
thirds of HCV patients were immigrants from Eastern Europe. HCV genotype 1 was 
predominant (67%). Over a third of patients had at least one recorded purchase of 
interferon, and treated patients were less likely to have chronic diseases such as 
diabetes or cardiovascular disease, compared to untreated patients. cOnclusiOns: 
The establishment of a HCV cohort in MHS can serve as a basis for retrospective 
database studies and can be periodically updated to follow up existing patients and 
identify incident HCV cases. For example, future studies can examine the adherence 
and efficacy of treatments, and associations between HCV and chronic diseases 
such as chronic kidney disease.
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Objectives: The objective of this study was to investigate the incidence of complica-
tions (bleeding and perforation) with hospitalization from both upper and lower GI 
tract in Japanese population using a health care claims database (HDB). MethOds: 
All of the claims data of the patients who have a history of hospitalization due to 
complications from GI tracts between January 2011 and December 2012 were extracted 
from the HDB which holds about 1.8 million peoples’ claims data under employment-
based health insurance. In order to identify upper and lower GI events precisely, we 
confirmed them when a diagnosis of a GI event in the claims (ICD-10 code) was accom-
panied by a record of examination and/or endoscopic or surgical treatment relevant 
to upper and lower GI complications. Results: The total number of person-years at 
risk was 1.2 million person-years in 2012. The incidence rates in upper and lower GI 
events were 48 and 41 per 100,000 person-years, respectively. Twenty-one percent of 
the lower events originated in bleeding from hemorrhoid or related treatments (eg. 
hemorrhoidectomy). Age-group analyses in the upper vs. lower events, except those 
from hemorrhoid, were 27 vs. 17, 57 vs. 46 and 184 vs. 104 per 100,000 person-years 
in 20-39, 40-59, and 60+ years groups, respectively. Data from 2011 were consistent 
with these observations on the ratio of upper to lower GI events and the age-based 
incidence, indicating the robustness of the results. cOnclusiOns: This was the first 
study to investigate the incidence from both upper and lower GI complications with 
hospitalization in a real clinical setting in Japan using a single large data source. We 
confirmed that a number of GI events occurred in both upper and lower GI tract and 
the incidence rates of both events were increased with age in a real world setting.
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associaTions BeTween crohn’s Disease severiTy anD sPecific socio-
DemograPhic, QualiTy-of-life anD coPing facTors
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